The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 15, 2016
Filed:
Nov. 08, 2013
Applicant:
Critical Outcome Technologies Inc., London, CA;
Inventor:
Wayne R. Danter, London, CA;
Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 31/704 (2006.01); A61K 31/337 (2006.01); A61K 31/439 (2006.01); A61K 31/555 (2006.01); A61K 31/496 (2006.01); C07D 215/40 (2006.01); C07D 401/12 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); A61K 33/24 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07D 215/40 (2013.01); A61K 31/337 (2013.01); A61K 31/439 (2013.01); A61K 31/496 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 33/24 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 471/04 (2013.01); C07D 471/14 (2013.01);
Abstract
A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.